Paul, Weiss, Rifkind, Whatron & Garris

500 Delaware Avenue, Wilmington, DE 19801

Verdict much lower, but AbbVie wants $3.2M award tossed in second testosterone class action test trial

By Dan Churney | Monday, Apr 30, 2018 @ 5:59pm

North Chicago-based drugmaker AbbVie is resisting what it is calling a jury's “confused and inconsistent” $3.2 million verdict, after the company lost a second trial in Chicago federal court – one in which it was ordered to pay $147 million less than the first trial – over a man’s claims AbbVie allegedly failed to warn its product AndroGel could bring on a heart attack.